S. Tomassetti (Forlì, Italy), F. Bonella (Essen, Germany)
Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion
K. Oishi, K. Aoe, Y. Murata, K. Sakamoto, T. Ohfuji, W. Kotoku, Y. Ogata, T. Matsumoto, H. Ueoka, Y. Mimura (Ube, Japan)
|   |
Survival in IPF acute exacerbations: The non-steroid approach
S. Papiris, K. Kagouridis, L. Kolilekas, A. Roussou, C. Triantafillidou, K. Baou, A. Papaporfyriou, G. Papadaki, K. Vougas, K. Malagari, S. Loukides, A. Kotanidou, A. Karakatsani, E. Manali (Athens, Greece)
| |
Familial pulmonary fibrosis: Clinical-functional and radiological features
D. Bennett, M. A. Mazzei, F. Mezzasalma, R. M. Refini, E. Bargagli, L. Volterrani, P. Rottoli (Siena, Italy)
| |
Distinct clinical and pathological phenotypes in IPF
E. Balestro, F. Calabrese, F. Rea, E. Rossi, F. Lunardi, M. Schiavon, E. Bazzan, M. Loy, G. Marulli, N. Nannini, G. Turato, S. Baraldo, M. Cosio, M. Saetta (Padova, Italy)
| |
Sleep desaturation and pulmonary hypertension determine sleep-related quality of life and depression in idiopathic pulmonary fibrosis
L. Kolilekas, E. Manali, P. Lyberopoulos, K. Vlami, C. Triantafillidou, K. Kagouridis, S. Gyftopoulos, K. Vougas, M. Gaga, A. Karakatsani, M. Alchanatis, S. Papiris (Athens, Greece)
| |
Predicting survival in interstitial lung disease (ILD): Multidisciplinary team (MDT) diagnosis versus technetium-99m diethylene triamine pentacetic acid (DTPA) clearance scans
A. Dwarakanath, S. S. Win, M. Elliiott, M. Darby, P. Beirne (Leeds, United Kingdom)
| |
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice
N. Manitsopoulos, N. Maniatis, I. Nikitopoulou, C. Magkou, A. Armaganidis, A. Kotanidou, S. Orfanos (Athens, Greece)
| |
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
J. Burgess, J. Jaffar, S. Unger, M. Keller, T. Corte, P. Wolters, L. Richeldi, S. Cerri, W. S. Argraves, J. Black, B. Oliver (Glebe, Sydney, Camperdown, Australia; San Francisco, Charleston, United States Of America; Modena, Italy)
| |
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
A. Giménez, F. Fernández, R. Galgoczy, A. Xaubet, D. Navajas, N. Reguart, A. Perera, J. Alcaraz (Barcelona, Spain)
| |
Quantitative analysis of pulmonary cysts and emphysema on computed tomography: Lymphangioleiomyomatosis, Birt-Hogg-Dubé syndrome and chronic obstructive lung disease
K. Tobino, T. Hirai, T. Johkoh, K. Fujimoto, M. Kurihara, K. Seyama (Iizuka, Itami, Kurume, Setagaya-Ku, Bunkyo-Ku, Japan; Sakyo-Ku, Jordan)
| |
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
M. Wygrecka, B. D. Dahal, D. Kosanovic, F. Petersen, B. Taborski, S. von Gerlach, M. Didiasova, D. Zakrzewicz, K. T. Preissner, R. T. Schermuly, P. Markart (Giessen, Borstel, Germany)
| |
Platelet-endothelial adhesion in IPF
M. Crooks, A. Morice, K. Naseem, S. Hart (Hull, United Kingdom)
| |
Changes in the small airways in idiopathic pulmonary fibrosis
S. Willems, S. Verleden, J. McDonough, B. Vanaudenaerde, G. Verleden, M. Decramer, J. Verschakelen, J. Hogg, W. Wuyts (Leuven, Belgium; Vancouver, Canada)
| |
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
K. Ikeda, M. Shiratori, K. Yokoo, M. Ohtsuka, H. Chiba, H. Takahashi (Sapporo, Japan)
| |
A prothrombotic state is associated with increased mortality in idiopathic pulmonary fibrosis
V. Navaratnam, A. Fogarty, T. McKeever, N. Thompson, G. Jenkins, S. Johnson, G. Dolan, M. Kumaran, K. Pointon, R. Hubbard (Nottingham, United Kingdom)
| |
Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis
M. Shioya, M. Otsuka, Y. Kitamura, K. Yokoo, K. Ikeda, H. Nishikiori, M. Shiratori, H. Takahashi (Sapporo, Japan)
| |
Severe lung inflammation is a feature of IPF
E. Rossi, E. Balestro, F. Calabrese, G. Turato, E. Bazzan, F. Lunardi, M. Schiavon, M. Damin, S. Baraldo, F. Rea, M. Saetta, M. Cosio (Padova, Italy)
| |
Combined pirfenidone, proton pump inhibitor and N-acetylcystein (PINPOINT) in IPF: Preliminary results
P. Chhajed, P. Shah, N. Shukla, N. Nester, D. Miedinger, J. Leuppi, A. Kate (Navi Mumbai, Mumbai, India)
| |